Report Detail

Request for Sample of this report

Pharma & Healthcare Global Neuroblastoma Chemotherapy Drugs Market Research Report 2022

  • RnM4441028
    • |
  • 18 May, 2022
    • |
  • Global
    • |
  • 96 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Summary:

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
Industry Insights
Due to the COVID-19 pandemic, the global Neuroblastoma Chemotherapy Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Neuroblastoma Chemotherapy Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Neuroblastoma Chemotherapy Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cyclophosphamide accounting for % of the Neuroblastoma Chemotherapy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Neuroblastoma Chemotherapy Drugs include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare and etc. In terms of revenue, the global 3 largest players have a % market share of Neuroblastoma Chemotherapy Drugs in 2021.
This report focuses on Neuroblastoma Chemotherapy Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Neuroblastoma Chemotherapy Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Post-covid-19 Outlook
The readers in the section will understand how the Neuroblastoma Chemotherapy Drugs market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Segmental Outlook
Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
Segment by Type
Cyclophosphamide
Cisplatin or Carboplatin
Vincristine
Doxorubicin (Adriamycin)
Etoposide
Other
Segment by Application
Hospital
Clinic
Other
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Competitive Scenario
In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
Frequently Asked Questions
Which product segment grabbed the largest share in the Neuroblastoma Chemotherapy Drugs market?
How is the competitive scenario of the Neuroblastoma Chemotherapy Drugs market?
Which are the key factors aiding the Neuroblastoma Chemotherapy Drugs market growth?
Which are the prominent players in the Neuroblastoma Chemotherapy Drugs market?
Which region holds the maximum share in the Neuroblastoma Chemotherapy Drugs market?
What will be the CAGR of the Neuroblastoma Chemotherapy Drugs market during the forecast period?
Which application segment emerged as the leading segment in the Neuroblastoma Chemotherapy Drugs market?
What key trends are likely to emerge in the Neuroblastoma Chemotherapy Drugs market in the coming years?
What will be the Neuroblastoma Chemotherapy Drugs market size by 2028?
Which company held the largest share in the Neuroblastoma Chemotherapy Drugs market?


Table of Contents

    1 Neuroblastoma Chemotherapy Drugs Market Overview

    • 1.1 Product Overview and Scope of Neuroblastoma Chemotherapy Drugs
    • 1.2 Neuroblastoma Chemotherapy Drugs Segment by Type
      • 1.2.1 Global Neuroblastoma Chemotherapy Drugs Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 Cyclophosphamide
      • 1.2.3 Cisplatin or Carboplatin
      • 1.2.4 Vincristine
      • 1.2.5 Doxorubicin (Adriamycin)
      • 1.2.6 Etoposide
      • 1.2.7 Other
    • 1.3 Neuroblastoma Chemotherapy Drugs Segment by Application
      • 1.3.1 Global Neuroblastoma Chemotherapy Drugs Sales Comparison by Application: (2022-2028)
      • 1.3.2 Hospital
      • 1.3.3 Clinic
      • 1.3.4 Other
    • 1.4 Global Neuroblastoma Chemotherapy Drugs Market Size Estimates and Forecasts
      • 1.4.1 Global Neuroblastoma Chemotherapy Drugs Revenue 2017-2028
      • 1.4.2 Global Neuroblastoma Chemotherapy Drugs Sales 2017-2028
      • 1.4.3 Neuroblastoma Chemotherapy Drugs Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Neuroblastoma Chemotherapy Drugs Market Competition by Manufacturers

    • 2.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Neuroblastoma Chemotherapy Drugs Manufacturing Sites, Area Served, Product Type
    • 2.5 Neuroblastoma Chemotherapy Drugs Market Competitive Situation and Trends
      • 2.5.1 Neuroblastoma Chemotherapy Drugs Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Neuroblastoma Chemotherapy Drugs Players Market Share by Revenue
      • 2.5.3 Global Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario by Region

    • 3.1 Global Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
      • 3.3.1 North America Neuroblastoma Chemotherapy Drugs Sales by Country
      • 3.3.2 North America Neuroblastoma Chemotherapy Drugs Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
      • 3.4.1 Europe Neuroblastoma Chemotherapy Drugs Sales by Country
      • 3.4.2 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Region
      • 3.5.2 Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
      • 3.6.1 Latin America Neuroblastoma Chemotherapy Drugs Sales by Country
      • 3.6.2 Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
      • 3.6.6 Colombia
    • 3.7 Middle East and Africa Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Neuroblastoma Chemotherapy Drugs Sales by Country
      • 3.7.2 Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Neuroblastoma Chemotherapy Drugs Historic Market Analysis by Type

    • 4.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
    • 4.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2017-2022)
    • 4.3 Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2022)

    5 Global Neuroblastoma Chemotherapy Drugs Historic Market Analysis by Application

    • 5.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
    • 5.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2017-2022)
    • 5.3 Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Baxter Healthcare
      • 6.1.1 Baxter Healthcare Corporation Information
      • 6.1.2 Baxter Healthcare Description and Business Overview
      • 6.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.1.5 Baxter Healthcare Recent Developments/Updates
    • 6.2 Ingenus Pharmaceuticals
      • 6.2.1 Ingenus Pharmaceuticals Corporation Information
      • 6.2.2 Ingenus Pharmaceuticals Description and Business Overview
      • 6.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
    • 6.3 ANI Pharmaceuticals
      • 6.3.1 ANI Pharmaceuticals Corporation Information
      • 6.3.2 ANI Pharmaceuticals Description and Business Overview
      • 6.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.3.5 ANI Pharmaceuticals Recent Developments/Updates
    • 6.4 Teva Pharmaceuticals
      • 6.4.1 Teva Pharmaceuticals Corporation Information
      • 6.4.2 Teva Pharmaceuticals Description and Business Overview
      • 6.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.4.5 Teva Pharmaceuticals Recent Developments/Updates
    • 6.5 Qilu Pharmaceutical
      • 6.5.1 Qilu Pharmaceutical Corporation Information
      • 6.5.2 Qilu Pharmaceutical Description and Business Overview
      • 6.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.5.5 Qilu Pharmaceutical Recent Developments/Updates
    • 6.6 Pfizer
      • 6.6.1 Pfizer Corporation Information
      • 6.6.2 Pfizer Description and Business Overview
      • 6.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.6.5 Pfizer Recent Developments/Updates
    • 6.7 Hikma Pharmaceuticals
      • 6.6.1 Hikma Pharmaceuticals Corporation Information
      • 6.6.2 Hikma Pharmaceuticals Description and Business Overview
      • 6.6.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.7.5 Hikma Pharmaceuticals Recent Developments/Updates
    • 6.8 Fresenius Kabi
      • 6.8.1 Fresenius Kabi Corporation Information
      • 6.8.2 Fresenius Kabi Description and Business Overview
      • 6.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.8.5 Fresenius Kabi Recent Developments/Updates
    • 6.9 Accord Healthcare
      • 6.9.1 Accord Healthcare Corporation Information
      • 6.9.2 Accord Healthcare Description and Business Overview
      • 6.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.9.5 Accord Healthcare Recent Developments/Updates
    • 6.10 Viatris
      • 6.10.1 Viatris Corporation Information
      • 6.10.2 Viatris Description and Business Overview
      • 6.10.3 Viatris Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Viatris Neuroblastoma Chemotherapy Drugs Product Portfolio
      • 6.10.5 Viatris Recent Developments/Updates

    7 Neuroblastoma Chemotherapy Drugs Manufacturing Cost Analysis

    • 7.1 Neuroblastoma Chemotherapy Drugs Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
    • 7.4 Neuroblastoma Chemotherapy Drugs Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Neuroblastoma Chemotherapy Drugs Distributors List
    • 8.3 Neuroblastoma Chemotherapy Drugs Customers

    9 Neuroblastoma Chemotherapy Drugs Market Dynamics

    • 9.1 Neuroblastoma Chemotherapy Drugs Industry Trends
    • 9.2 Neuroblastoma Chemotherapy Drugs Market Drivers
    • 9.3 Neuroblastoma Chemotherapy Drugs Market Challenges
    • 9.4 Neuroblastoma Chemotherapy Drugs Market Restraints

    10 Global Market Forecast

    • 10.1 Neuroblastoma Chemotherapy Drugs Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Neuroblastoma Chemotherapy Drugs by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Neuroblastoma Chemotherapy Drugs by Type (2023-2028)
    • 10.2 Neuroblastoma Chemotherapy Drugs Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Neuroblastoma Chemotherapy Drugs by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Neuroblastoma Chemotherapy Drugs by Application (2023-2028)
    • 10.3 Neuroblastoma Chemotherapy Drugs Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Neuroblastoma Chemotherapy Drugs by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Neuroblastoma Chemotherapy Drugs by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:
      Get latest Market Research Reports on Neuroblastoma Chemotherapy Drugs. Industry analysis & Market Report on Neuroblastoma Chemotherapy Drugs is a syndicated market report, published as Global Neuroblastoma Chemotherapy Drugs Market Research Report 2022. It is complete Research Study and Industry Analysis of Neuroblastoma Chemotherapy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      		$2,900.00
      		$5,800.00
      		2,328.70
      		4,657.40
      		2,723.10
      		5,446.20
      		448,166.00
      		896,332.00
      		242,382.00
      		484,764.00
      Credit card Logo
      Sample Question Discount Download PDF

      Related Reports

      Reason to Buy

      • Trusted By Leaders

        Top executives from leading companies purchase research reports from us. 

      • Shop With Confidence

        We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

      • Customer Centric

        Need assistance related to your research requirements? We are just a phone call or an email away.

      • Personalized Solutions

        Our experienced research specialists are here to help you locate the right reports for your need.

      • Secure Checkout

        Shop without being worried about safety & security of your transactions.
        •

      Request for Sample of this report

      Reports and Markets

      mcafree

      Contact Us

      +1-352-353-0818 (US)

      info@reportsandmarkets.com

      Support

      EMAIL US

      Newsletter

      KEEP UP TO DATE ON ALL THE LATEST REPORTS


      maxmind_logo